Atara Biotherapeutics (ATRA) Competitors $8.82 +0.11 (+1.26%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$8.80 -0.03 (-0.28%) As of 06/13/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ATRA vs. KOD, NVCT, INBX, PRQR, MNPR, ELDN, ESPR, VYGR, DERM, and DMACShould you be buying Atara Biotherapeutics stock or one of its competitors? The main competitors of Atara Biotherapeutics include Kodiak Sciences (KOD), Nuvectis Pharma (NVCT), Inhibrx (INBX), ProQR Therapeutics (PRQR), Monopar Therapeutics (MNPR), Eledon Pharmaceuticals (ELDN), Esperion Therapeutics (ESPR), Voyager Therapeutics (VYGR), Journey Medical (DERM), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry. Atara Biotherapeutics vs. Its Competitors Kodiak Sciences Nuvectis Pharma Inhibrx ProQR Therapeutics Monopar Therapeutics Eledon Pharmaceuticals Esperion Therapeutics Voyager Therapeutics Journey Medical DiaMedica Therapeutics Kodiak Sciences (NASDAQ:KOD) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability. Do institutionals & insiders have more ownership in KOD or ATRA? 89.1% of Kodiak Sciences shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 45.3% of Kodiak Sciences shares are held by insiders. Comparatively, 4.0% of Atara Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend KOD or ATRA? Kodiak Sciences currently has a consensus price target of $9.00, indicating a potential upside of 131.96%. Atara Biotherapeutics has a consensus price target of $17.75, indicating a potential upside of 101.25%. Given Kodiak Sciences' higher possible upside, analysts plainly believe Kodiak Sciences is more favorable than Atara Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kodiak Sciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Atara Biotherapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57 Does the media favor KOD or ATRA? In the previous week, Kodiak Sciences had 2 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 4 mentions for Kodiak Sciences and 2 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 1.78 beat Kodiak Sciences' score of 0.08 indicating that Atara Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Atara Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Does the MarketBeat Community prefer KOD or ATRA? Atara Biotherapeutics received 418 more outperform votes than Kodiak Sciences when rated by MarketBeat users. Likewise, 67.33% of users gave Atara Biotherapeutics an outperform vote while only 26.76% of users gave Kodiak Sciences an outperform vote. CompanyUnderperformOutperformKodiak SciencesOutperform Votes1926.76% Underperform Votes5273.24% Atara BiotherapeuticsOutperform Votes43767.33% Underperform Votes21232.67% Which has more risk and volatility, KOD or ATRA? Kodiak Sciences has a beta of 2.27, meaning that its share price is 127% more volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500. Which has better earnings and valuation, KOD or ATRA? Kodiak Sciences has higher earnings, but lower revenue than Atara Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKodiak SciencesN/AN/A-$260.49M-$3.63-1.07Atara Biotherapeutics$199.73M0.26-$276.13M-$3.72-2.37 Is KOD or ATRA more profitable? Kodiak Sciences has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -132.58%. Atara Biotherapeutics' return on equity of 0.00% beat Kodiak Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Kodiak SciencesN/A -84.52% -45.40% Atara Biotherapeutics -132.58%N/A -90.16% SummaryKodiak Sciences and Atara Biotherapeutics tied by winning 9 of the 18 factors compared between the two stocks. Get Atara Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATRA vs. The Competition Export to ExcelMetricAtara BiotherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$52.58M$3.09B$5.57B$8.50BDividend YieldN/A1.56%5.28%4.16%P/E Ratio-0.3432.6326.6319.64Price / Sales0.26455.18407.99152.17Price / CashN/A168.6838.2534.64Price / Book-0.363.366.964.60Net Income-$276.13M-$72.35M$3.23B$248.06M7 Day Performance-4.44%0.30%-1.05%-0.87%1 Month Performance33.43%16.40%8.65%3.58%1 Year Performance-30.96%-15.52%33.67%14.04% Atara Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATRAAtara Biotherapeutics4.3539 of 5 stars$8.82+1.3%$17.75+101.2%-33.1%$52.58M$199.73M-0.34330Positive NewsKODKodiak Sciences4.2958 of 5 stars$3.60+5.9%$9.00+150.0%+40.6%$189.95MN/A-0.9990Short Interest ↓Gap DownNVCTNuvectis Pharma2.9463 of 5 stars$8.98-4.6%$17.00+89.3%+23.1%$187.63MN/A-7.748News CoveragePositive NewsINBXInhibrx2.8918 of 5 stars$12.96-3.8%N/A-12.2%$187.61M$200K0.11166Positive NewsUpcoming EarningsGap DownPRQRProQR Therapeutics1.9649 of 5 stars$1.78+7.2%$8.00+349.4%+5.0%$187.28M$18.97M-5.56180Positive NewsAnalyst RevisionMNPRMonopar Therapeutics2.8536 of 5 stars$30.01-5.4%$55.33+84.4%+633.2%$183.51MN/A-15.2310Gap DownELDNEledon Pharmaceuticals2.5879 of 5 stars$3.06+2.0%$12.50+308.5%-2.4%$183.24MN/A-1.5210Positive NewsESPREsperion Therapeutics4.0387 of 5 stars$0.92+8.1%$6.25+580.4%-59.8%$182.07M$259.57M-1.44200Analyst RevisionVYGRVoyager Therapeutics4.4109 of 5 stars$3.29+20.1%$13.39+307.0%-62.5%$182.06M$66.96M4.63100Analyst RevisionGap UpHigh Trading VolumeDERMJourney Medical2.2717 of 5 stars$7.81-3.1%$9.88+26.4%+26.3%$181.94M$56.24M-8.3190Positive NewsAnalyst DowngradeShort Interest ↑High Trading VolumeDMACDiaMedica Therapeutics1.3123 of 5 stars$4.17+1.5%$8.00+91.8%+55.3%$178.82MN/A-7.4520Short Interest ↑ Related Companies and Tools Related Companies KOD Alternatives NVCT Alternatives INBX Alternatives PRQR Alternatives MNPR Alternatives ELDN Alternatives ESPR Alternatives VYGR Alternatives DERM Alternatives DMAC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATRA) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
